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The extremely low efficiency of human embryonic
stem cell (hESC) derivation using somatic cell nu-
clear transfer (SCNT) limits its potential application.
Blastocyst formation from human SCNT embryos oc-
curs at a low rate and with only some oocyte donors.
We previously showed in mice that reduction of his-
tone H3 lysine 9 trimethylation (H3K9me3) through
ectopic expression of the H3K9me3 demethylase
Kdm4d greatly improves SCNT embryo develop-
ment. Here we show that overexpression of a related
H3K9me3 demethylase KDM4A improves human
SCNT, and that, as in mice, H3K9me3 in the human
somatic cell genome is an SCNT reprogramming
barrier. Overexpression of KDM4A significantly
improves the blastocyst formation rate in human
SCNT embryos by facilitating transcriptional reprog-
ramming, allowing efficient derivation of SCNT-
derived ESCs using adult Age-related Macular
Degeneration (AMD) patient somatic nuclei donors.
This conserved mechanistic insight has potential
applications for improving SCNT in a variety of con-
texts, including regenerative medicine.
INTRODUCTION
The differentiated somatic cell genome can be reprogramed
back into an embryonic state when the nucleus is exposed to
the molecular milieu of the oocyte cytoplasm via somatic cell
nuclear transfer (SCNT) (Gurdon, 1962), thereby enabling the
generation of pluripotent embryonic stem cells (ESCs) from
terminally differentiated somatic cells (Wakayama et al., 2001).
Because SCNT-derived ESCs (NT-ESCs) are genetically autolo-758 Cell Stem Cell 17, 758–766, December 3, 2015 ª2015 Elsevier Ingous to the nuclear donor somatic cells, SCNT has great poten-
tial in therapeutic and regenerative medicine, including disease
modeling and cell/tissue replacement therapy (Hochedlinger
and Jaenisch, 2003; Yang et al., 2007). Thus, SCNT can be
used to fix mitochondria-gene-related defects, which cannot
be done through transcription-factor-based reprogramming
(Ma et al., 2015). Despite the great potential of human NT-
ESCs, technical difficulties makes its application to human
therapeutics extremely difficult (French et al., 2008; Noggle
et al., 2011; Simerly et al., 2003).
The first NT-ESCs were generated by the Mitalipov group us-
ing differentiated fetal and infant fibroblasts as nuclear donors
(Tachibana et al., 2013). Using their optimized conditions, we
and others succeeded in deriving human NT-ESCs from adult
and aged patient somatic cells (Chung et al., 2014; Yamada
et al., 2014). However, derivation of NT-ESCs still remains a
very difficult task due to the extremely low rate of SCNT embryos
developing to the blastocyst stage. Currently only oocytes with
the highest quality from certain females can support the devel-
opment of SCNT embryos to the blastocyst stage (Chung
et al., 2014; Tachibana et al., 2013), limiting the useful oocyte
donor pools.
The poor developmental potential of SCNT embryos is not
limited to human; it is also commonly observed in all examined
mammalian species (Rodriguez-Osorio et al., 2012). Through
comparative transcriptomic and epigenomic analyses of mouse
in vitro fertilization (IVF) and SCNT embryos, we have recently re-
vealed that histone H3 lysine 9 trimethylation (H3K9me3) in the
donor somatic cell genome functions as a barrier preventing
transcriptional reprogramming by SCNT, leading to failure of zy-
gotic genome activation (ZGA) and preimplantation develop-
ment (Matoba et al., 2014). Importantly, we demonstrated that
this epigenetic barrier could be removed by the ectopic overex-
pression of mouse Kdm4d, an H3K9me3 demethylase. Removal
of H3K9me3 facilitates ZGA and consequently improves devel-
opment of mouse SCNT embryos to reach the blastocyst stage,
leading to an increased rate of mouse NT-ESC establishmentc.
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Figure 1. Human RRRs Are Enriched for H3K9me3 in Somatic Cells
(A) Schematic illustration of the experimental procedures. Samples used for RNA-seq are marked by dashed rectangles.
(B) Heatmap illustration of the transcriptome of IVF human preimplantation embryos. Each tile represents an average of peaks within the region obtained by
sliding-window analysis. Shown are the 707 regions that are activated from the four-cell to the eight-cell stage in IVF embryos. RNA-seq datasets were obtained
from a previous publication (Xue et al., 2013).
(C) Heatmap illustration of the transcriptome comparing donor somatic cells, IVF embryos, and SCNT embryos at the eight-cell stage. Shown are the 707 regions
identified in (A). These regions were classified into three groups based on the fold-change (FC) in transcription levels between SCNT and IVF eight-cell embryos.
FRRs, PRRs, and RRRs indicate fully reprogrammed regions (FC % 2), partially reprogrammed regions (2 < FC % 5), and reprogramming-resistant regions
(FC > 5), respectively.
(D) The average ChIP-seq intensity of H3K9me3 and H3K4me3 in human fibroblast cells (Nhlf) are shown within FRR, PRR, and RRR compared with 200 kb
flanking regions. Histone modification ChIP-seq datasets were obtained from the ENCODE project (Bernstein et al., 2012; ENCODE Project Consortium, 2011).
(legend continued on next page)
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(Matoba et al., 2014). These findings prompted us to ask whether
the principle we discovered in mouse can be applied to human
SCNT.
Here we report that somatic cell H3K9me3 also serves as a
barrier in human SCNT reprogramming. We demonstrate that
KDM4A overexpression significantly improves human SCNT
embryo development, allowing efficient derivation of patient-
specific NT-ESCs using oocytes obtained from donors whose
oocytes failed to develop into blastocysts without the help of
KDM4A overexpression. Thus, our study expands the usability
of oocyte donors and establishes histone-demethylase-assisted
SCNT as a general method for improving mammalian SCNT for
reproductive and therapeutic cloning.
RESULTS
Identification of Reprogramming-Resistant Regions in
Eight-Cell Human SCNT Embryos
Human ZGA takes place during the late four-cell to the late eight-
cell stages (Niakan et al., 2012) (Figure 1A). To identify the
genomic regions activated during ZGA of normal human IVF em-
bryos, we analyzed published human preimplantation embryo
RNA-sequencing (RNA-seq) datasets (Xue et al., 2013) and iden-
tified 707 genomic regions ranging from 20 to 160 kb in size
(Table S1) that were activated at least 5-fold at the eight-cell
stage compared to the four-cell stage (Figure 1B).
To determine whether ZGA takes place properly in human
SCNT, we collected late eight-cell stage embryos (five/group),
derived either from SCNT or IVF, and performed RNA-seq (Fig-
ure 1A). In parallel, we also performed RNA-seq of the donor
dermal fibroblast cells (DFB-8, see Experimental Procedures).
Analysis of the 707 genomic regions defined above (Figure 1B,
Table S1) indicates that the majority of the ZGA regions are acti-
vated in the SCNT embryos compared to those in donor fibro-
blasts (Figure 1C). However, the level of activation is not compa-
rable to that in IVF embryos (Figure 1C). Of the 707 genomic
regions, 169 were activated at a level comparable to those in
IVF embryos (FC% 2, IVF versus SCNT), and were thus termed
fully reprogrammed regions (FRRs) following our previous defini-
tion (Matoba et al., 2014). Similarly, 220 regions were partially
activated (2 < FC % 5) in SCNT compared to IVF embryos and
were termed partially reprogrammed regions (PRRs). However,
the remaining 318 regions (Table S2), termed reprogramming-
resistant regions (RRRs), failed to be activated in SCNT embryos
(FC > 5). Thus, comparative transcriptome analysis allowed us to
identify 318 RRRs that were refractory to transcriptional reprog-
ramming in human eight-cell SCNT embryos.
The Heterochromatin Features of RRRs Are Conserved
in Human Somatic Cells
We next asked whether the human RRRs possess the hetero-
chromatin features like those of the mouse RRRs. Analysis of
the publically available ChIP-seq datasets of eight major histone(E and F) Boxplots comparing the average intensity of H3K9me3-ChIP-seq (E) and
seq and DNaseI-seq datasets were obtained from the ENCODE projects (ENCO
median, the edges indicate the 25th/75th percentiles, and the whiskers indicate t
See also Figure S1, Table S1, and Table S2.
760 Cell Stem Cell 17, 758–766, December 3, 2015 ª2015 Elsevier Inmodifications from human fibroblast cells (Bernstein et al., 2012;
ENCODE Project Consortium, 2011) revealed specific enrich-
ment of H3K9me3 in human RRRs (Figures 1D and S1A).
The enrichment of H3K9me3 is unique to RRRs, as a similar
enrichment was not observed in FRRs or PRRs (Figures 1D
and S1A). Similar analysis also revealed the enrichment of
H3K9me3 at RRRs in K562 erythroleukemic cells, Hsmm skeletal
muscle myoblasts, and Mcf7 breast adenocarcinoma cells (Fig-
ures 1E and S1B), indicating that H3K9me3 enrichment in RRRs
is a common feature of somatic cells.
Next, we analyzed the DNaseI hypersensitivity of four different
somatic cell types using the datasets generated by the ENCODE
project. The analysis revealed that RRRs are significantly less
sensitive to DNaseI compared to FRR and PRR in all human so-
matic cell types analyzed (Figures 1F and S1C). Consistent with
their heterochromatin feature, human RRRs are relatively gene-
poor compared to FRRs or PRRs (Figure S1D), and they are en-
richedwith specific repeat sequences such as LINE and LTR, but
not SINE (Figure S1E). Collectively, these results indicate that the
heterochromatin features of RRRs, enrichment of H3K9me3, and
decreased accessibility to DNaseI are conserved in both mouse
and human somatic cells.
Human KDM4A mRNA Injection Improves Development
of Mouse SCNT Embryos
Having established that humanRRRs are enriched for H3K9me3,
we next asked whether removal of H3K9me3 could help over-
come the reprogramming barrier in human SCNT embryos. We
previously demonstrated using a mouse SCNT model that the
H3K9me3 barrier could be removed by injection of mRNAs en-
coding the mouse H3K9me3 demethylase Kdm4d (Matoba
et al., 2014). Before moving into a human SCNT model, given
that multiple members of the KDM4 family with H3K9me3 deme-
thylase activity exist in mouse and human (Klose et al., 2006;
Krishnan andTrievel, 2013;Whetstine et al., 2006), wewere inter-
ested in determining whether the effect of Kdm4d in facilitating
SCNT reprogramming could be extended to other members of
the KDM4 family. In addition, we were also interested in testing
whether KDM4 family members could function across species.
To this end, we performed SCNT using cumulus cells of adult
female mice as nuclear donors and injected human KDM4A
mRNA at 5 hr post-activation (hpa) following the same procedure
used in our previous study (Figure 2A) (Matoba et al., 2014). Im-
munostaining revealed that injection of WT, but not catalytic
mutant, human KDM4A mRNA greatly reduced H3K9me3 levels
in the nucleus of mouse SCNT embryos (Figure 2B). Importantly,
injection of KDM4A mRNA greatly increased the developmental
potential of SCNT embryos with 90.3% of them developing to
the blastocyst stage, which is in contrast to the 26% blastocyst
formation rate in controls (Figures 2C and 2D, Table S3). The
extremely high efficiency of blastocyst formation is similar
to the 88.6% observed in Kdm4d-injected mouse SCNT em-
bryos (Matoba et al., 2014). These results suggest that theDNaseI-seq (F) within FRR, PRR, and RRR in different somatic cell types. ChIP-
DE Project Consortium, 2011). Middle line in the colored space indicates the
he 2.5th/97.5th percentiles. ***p < 0.001, **p < 0.01.
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reprogramming barrier, H3K9me3 in the somatic cell genome,
can be removed by any member of the KDM4 family demethy-
lases as long as it contains H3K9me3 demethylase activity.
KDM4A mRNA Injection Significantly Increases the
Blastocyst Formation Rate of Human SCNT Embryos
We next asked whether KDM4A mRNA injection could also help
overcome the reprogramming barrier in human SCNT using the
optimized SCNT conditions including the use of the histone de-
acetylase inhibitor Trichostatin A (TSA) (Tachibana et al., 2013).
With the future clinical application of KDM4A-assisted SCNT in
mind, we used dermal fibroblasts of Age-relatedMacular Degen-
eration (AMD) patients as nuclear donors.
To reaffirm the beneficial effect of KDM4A on human SCNT, we
chose oocyte donors whose oocytes failed to develop to the
expandedblastocyst inourpast attemptsusing the regularproce-
dures (Chunget al., 2014). Followingenucleation, a total of 114MII
oocytes collected from four oocyte donors were fused to donor
fibroblast cells by HVJ-E (Hemagglutinating virus of Japan enve-
lope). Upon activation, 63 of the reconstructed SCNT oocytes
were injectedwith humanKDM4AmRNA, and the rest (51) served
as non-injected controls (Figure 2E, Table S4). We monitored the
developmental process of these SCNT embryos and found that
the two groups featured similar cleavage efficiencies to form
two-cell embryos (control: 48/51 = 94.1%, KDM4A: 56/63 =
88.9%) (Table S4). As expected, KDM4A mRNA injection did not
showanybeneficial effecton thedevelopmental rate ofSCNTem-
bryosbeforeZGAfinishesat theendof theeight-cell stage (68.8%
versus 71.4%) (Figure 2F and Table S4). However, the beneficial
effect became clear at the morula stage (16.7% versus 32.1%)
(Figure 2F and Table S4). Strikingly, at day 6, 26.8% (15/56) of
the KDM4A-injected embryos had successfully reached the blas-
tocyst stage, ascompared toonly4.2% (2/48) of control embryos.
On day 7, 14.3% of KDM4A-injected embryos developed to the
expanded blastocyst stage, while none of the control embryos
developed into this stage (Figures 2F and 2G). Importantly, the
beneficial effect of KDM4Awas observed in all four donors exam-
ined (Figure 2H). Thus we conclude that KDM4A mRNA injection
can improve the developmental potential of human SCNT em-
bryos, especially beyond ZGA.
Establishment and Characterization of Human ESCs
Derived from KDM4A-Injected SCNT Blastocysts
We next attempted to derive NT-ESCs from KDM4A-injected
SCNT blastocysts. We obtained a total of eight expanded
blastocysts from KDM4A-injected SCNT embryos (Figure 3AFigure 2. Injection of Human KDM4A mRNA Improves Development of
(A) Schematic illustration of the mouse SCNT procedures.
(B) Representative nuclear images of one-cell stage SCNT embryos stained with
(C) KDM4A mRNA injection greatly improves preimplantation development of m
indicated stages. Error bars indicate SD.
(D) Representative images of SCNT embryos after 120 hr of culturing in vitro. Sc
(E) Schematic illustration of the human SCNT procedures.
(F) Bar graph showing the average developmental efficiency of human SCNT emb
culture. The efficiency was calculated using the number of embryos that reache
opmental rates were statistically analyzed by Fisher’s exact test.
(G) Representative images of SCNT embryos after 7 days of culturing in vitro.
(H) Bar graphs showing the developmental rate of human SCNT embryos derive
See also Tables S3 and S4.
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expanded blastocysts were cultured on irradiated mouse em-
bryonic fibroblasts (MEFs) in a conventional ESC derivation
medium. Seven out of the eight blastocysts attached to the
MEF feeder cells and initiated outgrowth. After five passages,
we successfully derived four stable NT-ESC lines, which were
designated as NTK (NT assisted by KDM4A)-ESC #6–9, respec-
tively (Figure 3A, also named CHA-NT #6–9).
Immunostaining revealed that OCT4, NANOG, SOX2, SSEA-4,
and TRA1-60 were all expressed with similar patterns to those of
a control human ESC line derived by IVF (Figures 3B, S2A, and
S2B).RNA-seq (FigureS2C) revealed that theNTK-ESCsexpress
pluripotency marker genes at levels similar to those of control
ESCs (Figure 3C). Pairwise comparison of global transcriptomes
revealed ahigh correlation betweenNTK-ESCsand control ESCs
(Figures 3D and S2D). Hierarchical clustering analyses of tran-
scriptomes revealed that NTK-ESCs are clustered together with
control ESCs (Figure 3E). These results suggest that NTK-ESCs
are indistinguishable from control ESCs at the molecular level.
We next examined the differentiation capacity of the NTK-
ESCs by in vitro differentiation and in vivo teratoma assays.
Immunostaining of embryoid bodies (EBs) after 2 weeks of
in vitro culture revealed that the NTK-ESCs could efficiently
give rise to all three germ layer cells (Figures 3F and S2E). More-
over, the NTK-ESCs formed teratomas containing all three germ
layer cells within 12 weeks of transplantation (Figures 3G and
S2F). These results indicate that the NTK-ESCs are pluripotent.
Karyotyping demonstrated that these NTK-ESCs maintain a
normal number of chromosomes and have the same expected
pair of sex chromosomes as those of the nuclear donor somatic
cells (46, XX for NTK6/7; 46, XY for NTK8; Figures 3H and S3A).
Short TandemRepeat (STR) analysis demonstrated that all of the
16 repeat markers located across the genome showed a perfect
match between donor somatic cells and their derivative NTK-
ESCs (Figures 3I and S3B). mtDNA sequence analysis revealed
that both SNPs of NTK-ESCs matched exactly those of oocyte
donors, but not those of nuclear donors (Figures 3J and S3C).
Collectively, these results establish the reliability of our SCNT
method, and they demonstrate that KDM4A mRNA injection im-
proves SCNT-mediated ESC derivation without compromising
pluripotency or genomic stability of the established NTK-ESCs.
KDM4A Facilitates ZGA of RRRs in Eight-Cell SCNT
Embryos
The fact that KDM4A mRNA injection significantly improves
SCNT embryo development after ZGA suggested that H3K9me3Mouse and Human SCNT Embryos
anti-H3K9me3 and DAPI at 5 hr after mRNA injection.
ouse SCNT embryos. Shown is the percentage of embryos that reached the
ale bar, 100 mm.
ryos obtained using oocytes from four different donors during 7 days of in vitro
d the two-cell stage. Blast, blastocyst; ExBlast, expanded blastocyst. Devel-
d from each oocyte-donor female.
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Figure 3. Establishment and Characterization of NTK-ESCs from AMD Patients
(A) Summary of established NT-ESC lines using AMD patient fibroblasts as nuclear donors through KDM4A-assisted SCNT.
(B) Representative phase contrast and immunostaining images of NTK-ESCs. Scale bar, 100 mm.
(C) Bar graphs showing expression levels of pluripotency-specific and fibroblast-specific genes based on RNA-seq data.
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scription levels of two representative KDM4A-
responsive genes, UBTFL1 and THOC5, in IVF or
SCNT (with or without KDM4A mRNA injection)
eight-cell embryos.
See also Table S5.in donor somatic cell genome indeed functions as a barrier for
ZGA in human SCNT embryos, as is the case in mouse. To
determine to what extent the injection of KDM4A mRNAs could
overcome ZGA defects in the SCNT embryos, we performed
RNA-seq of eight-cell SCNT embryos with or without KDM4A in-
jection. Comparative transcriptome analyses indicated that as
much as 50% (158) of the 318 RRRs were markedly upregulated
by KDM4A mRNA injection (Figure 4A, FC > 2), indicating that
erasure of H3K9me3 can at least partly facilitate ZGA in SCNT
embryos.(D) Scatterplot comparing gene expression levels between a control ESC line (ESC15) and a representativ
(FC > 3.0) are shown as black dots.
(E) Hierarchical clustering of NTK-ESCs, control ESCs, and donor dermal fibroblast cells based on RNA-seq
(F) Representative images of immunostained embryoid bodies (EBs) spontaneously differentiated in vitro for
(G) Representative histological images of teratoma derived from NTK6 at 12 weeks after transplantation. Sc
(H) Representative images of cytogenetic G-banding analysis of NTK6.
(I) Nuclear DNA genotyping using 16 STR markers.
(J) mtDNA genotyping of a representative single nucleotide polymorphism (SNP) site.
See also Figures S2 and S3.
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help explain the improved development
of KDM4A-injected SCNT embryos, we
focused our analysis on genes (instead
of repeats or non-coding regions). We
identified 206 genes (Table S5) whose
expression was significantly upregulated
by KDM4A injection (FPKM > 5, FC > 2).
Gene ontology analysis revealed that
these genes were enriched for transcrip-
tional regulation, ribosomal biogenesis,
and RNA processing (Figure 4B), sug-
gesting that dysregulation of these devel-
opmentally important machineries might
be a cause of developmental arrest of
SCNT embryos. Although the function
of the majority of the 206 genes in
preimplantation development is currently
unknown, two of them, UBTFL1 and
THOC5 (Figure 4C), are known to be
required for normal preimplantation
development in mice (Wang et al., 2013;Yamada et al., 2010). Therefore, defective activation of these
genes is at least partly responsible for the poor development of
human SCNT embryos.
DISCUSSION
After decades of efforts, human NT-ESCs were finally derived
recently (Chung et al., 2014; Tachibana et al., 2013; Yamada
et al., 2014). These advances were mainly due to optimization
of SCNT derivation conditions. However, the intrinsic defectse NTK-ESC, NTK6. Differentially expressed genes
datasets.
2 weeks. Scale bar, 100 mm.
ale bar, 100 mm.
in epigenetic reprogramming that cause the developmental
arrest of human SCNT embryos have not been identified. In
this study, we demonstrate that similar to mouse, H3K9me3
in somatic cell genome presents a barrier for human SCNT re-
programming. Removal of this barrier by overexpressing the
H3K9me3 demethylase KDM4A facilitates transcriptional re-
programming at ZGA, thereby allowing human SCNT embryos
to develop more efficiently to generate blastocysts, from which
we successfully established multiple AMD-patient-specific
NT-ESC lines without compromising genomic stability or
pluripotency. Our study thus not only demonstrates that
H3K9me3 serves as a general reprogramming barrier, but it
also establishes a practical approach for improving cloning
efficiency.
It has been well known that the ability of human oocytes to
support SCNT embryo development varies greatly among
oocyte donors. Indeed, human NT-ESCs can be derived only
when high-quality oocytes donated by a small group of females
were used as recipients (Chung et al., 2014; Tachibana et al.,
2013; Yamada et al., 2014), although the reason for the depen-
dence on oocyte quality remains elusive. Consistently, oocytes
from only one (ID #58) out of the four donors supported SCNT
blastocyst formation without KDM4AmRNA injection even under
the presence of TSA, which has been reported to enhance blas-
tocyst formation (Tachibana et al., 2013) (Figure 2H and Table
S4). In contrast, oocytes of all four donors tested supported blas-
tocyst formation when KDM4A mRNAs were injected, indicating
that KDM4A can overcome the donor variation problem.
Whether KDM4A can improve IVF embryo development remains
to be determined.
Although the developmental potential of human SCNT em-
bryos reaching the blastocyst stage was significantly and
consistently improved by KDM4A mRNA injection, the magni-
tude of improvement was not as drastic as that of mice (90%
in mice versus 27% in human). One possible explanation to
this species difference is that the quality of human oocytes varies
greatly even within the same batch of oocytes derived from a sin-
gle ovulation, and only a fraction of them have the capacity to
support development to the blastocyst stage even by IVF, which
has a varying success rate of 15%–60% (Shapiro et al., 2002;
Stone et al., 2014). This is in clear contrast to mouse IVF where
more than 90% of embryos can develop to the blastocyst stage.
It is therefore possible that some of the human oocytes that we
used in our experiments could not support blastocyst formation
even by IVF.
In addition to demonstrating the efficacy of KDM4A in
improving human SCNT efficiency and NT-ESC derivation,
another important finding of this study is that KDM4A can facili-
tate both mouse and human SCNT reprogramming. Considering
that human KDM4A can function in mouse SCNT embryos to
achieve an effect similar to that of Kdm4d, it is likely that all mem-
bers of the KDM4 family can be used to facilitate SCNT as long
as they possess H3K9me3 demethylase activity. Given that
H3K9me3 in somatic genome functions as a reprogramming
barrier in both mouse and human, it is likely that this reprogram-
ming barrier might be conserved in other mammalian species as
well. If this is the case, our KDM4-assisted SCNTmethod should
be generally applicable to the cloning of other mammalian
species.CellIn summary, we have established an improved KDM4-assis-
ted SCNT method. Using this method, we derived blastocysts
from adult AMD patient cells and subsequently established
multiple NTK-ESCs with genomes identical to those of donor
patients. This provides unique and important cell sources for un-
derstanding AMD as well as for therapeutic drug screening for
AMD treatments. Given that the same strategy can be applied
to the studies of other human diseases, we anticipate that our
study will have a general impact on human therapeutics.
Additionally, since SCNT allows replacement of somatic cell
mitochondria with that of the recipient oocyte, as we have
demonstrated in this study (Figures 3H–3J and S3), it provides
an opportunity to treat mtDNA-related diseases. Indeed, a
recent study demonstrated that a metabolic syndrome pheno-
type caused by mtDNA mutation can be corrected by replacing
mtDNA through SCNT (Ma et al., 2015). Thus, our KDM4-assis-
ted SCNT method should be useful for mtDNA-replacement
therapies.EXPERIMENTAL PROCEDURES
Human SCNT Procedure and KDM4A mRNA Injection
All MII stage oocytes with distinctive first polar bodies were enucleated under
an inverted microscope equipped with a Poloscope (Oosight, Cambridge
Research & Instrumentation). The enucleation and nuclear donor cell fusion
were carried out in the presence of caffeine (1.25 mM). For enucleation, oo-
cytes were pre-incubated in Global HTFmediumwith HEPES (Life Global) con-
taining 0.5 mg/ml cytochalasin B and caffeine (1.25 mM) for 5 min. Then, the
spindle complex was removed using a PIEZO actuator (Primetech). Dermal
fibroblast cells resuspended in a drop containing HVJ-E extract (Cosmo Bio)
were inserted into the perivitelline space of the enucleated oocytes. The recon-
structed oocytes were kept in the manipulation medium containing caffeine
(1.25 mM) until cell fusion was confirmed, and then the reconstructed oocytes
were transferred into Global medium (10% SPS) and incubated for 1–1.5 hr
before activation. Activation was carried out by the application of electro-
pulses (23 50 ms DC pulses, 2.7 kV/cm) in 0.25 M d-sorbitol buffer and
6-DMAP (2mM, 4 hr) as previously described (Tachibana et al., 2013). The acti-
vated embryos were transferred to Global 10% SPS medium supplemented
with TSA (10 nM, Sigma) for 12 hr, and then the embryos were transferred to
Global 10% FBS without TSA and cultured for up to 7 days in an incubator
with an atmosphere of 6% CO2/5% O2/89% N2 at 37
C. The culture medium
was changed on day 3.
For mRNA injection, the activated SCNT embryos were washed and
cultured in Global 10% SPS for 1 hr before the KDM4A mRNA injection.
Approximately 10 pl of KDM4A mRNA was injected into the SCNT embryos
at 5 hr after activation in HEPES-HTF 10% SPS medium using a PIEZO actu-
ator as described previously (Matoba et al., 2014). More details on donor cell
preparation, mRNA preparation, RNA-seq, and other procedures can be found
in the Supplemental Experimental Procedures.
Identification of Human RRRs
A sliding window (size 20 kb, step size 10 kb) was used to assess the genome-
wide expression level of four-cell and eight-cell human embryos. For each
window, the expression level was quantified with normalized RPM (reads
per millions of uniquely mapped reads). The significantly activated regions in
eight-cell relative to four-cell IVF embryos were identified with stringent criteria
(FC > 5, RPM > 5 in eight-cell IVF embryos), and the overlapping regions were
merged. These activated regions were classed into three groups based on
their expression differences in human SCNT and IVF eight-cell embryos.ACCESSION NUMBERS
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